2-(10-chloro-8-(3-cyano-4-isopropoxybenzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetic acid | 1262007-64-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(10-chloro-8-(3-cyano-4-isopropoxybenzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetic acid
• 英文别名: 2-[10-chloro-8-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl]acetic acid
• CAS: 1262007-64-6
• 化学式: C₂₄H₂₃ClN₂O₅
• 分子量: 454.91
• InChiKey: HYVXPPQYQSOILH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(10-chloro-8-(3-cyano-4-isopropoxybenzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetic acid 生成 2-[(1R)-10-chloro-8-[(3-cyano-4-propan-2-yloxyphenyl)methoxy]-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl]acetic acid 、
  参考文献：
  名称：

  Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor

  摘要：

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.089
• 作为产物：
  描述：

  5-benzyloxy-1H-indole-2-carbaldehyde 在 N-氯代丁二酰亚胺 、 10 wt% Pd(OH)2 on carbon 、 四丁基氟化铵 、 甲酸铵 、 sodium hydride 、 potassium carbonate 、 cesium fluoride 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 2-(10-chloro-8-(3-cyano-4-isopropoxybenzyloxy)-3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-1-yl)acetic acid
  参考文献：
  名称：

  Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor

  摘要：

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.089

文献信息

• [EN] MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR SPHINGOSINE-1-PHOSPHATE (S1P) UTILES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CEUX-CI
  申请人：ARENA PHARM INC

  公开号：WO2011005295A8

  公开（公告）日：2012-09-20
• Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptor
  作者：Daniel J. Buzard、Thomas O. Schrader、Xiuwen Zhu、Juerg Lehmann、Ben Johnson、Michelle Kasem、Sun Hee Kim、Andrew Kawasaki、Luis Lopez、Jeanne Moody、Sangdon Han、Yinghong Gao、Jeff Edwards、Jeremy Barden、Jayant Thatte、Joel Gatlin、Robert M. Jones

  DOI：10.1016/j.bmcl.2014.11.089

  日期：2015.2

  Modulators of S1P(1) have proven utility for the treatment of autoimmune disease and efforts to identify new agents with improved safety and pharmacokinetic parameters are ongoing. Several new S1P(1) chemotypes were designed and optimized for potency and oral bioavailability. These new agents are characterized by a 'tricyclic fused indole array' and are highly potent agonists of the S1P(1) receptor. (C) 2014 Elsevier Ltd. All rights reserved.